Diffuse Large B Cell Lymphoma  >>  Tecentriq (atezolizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
LYSA, NCT03276468 / 2016-005061-31: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Completed
2
136
Europe
Atezolizumab, Tecentriq, Obinutuzumab, Gazyvaro, Venetoclax, Venclyxto
The Lymphoma Academic Research Organisation
Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue
09/19
08/22
ARGO, NCT03422523 / 2016-002654-21: Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

Terminated
2
53
Europe
Atezolizumab, Tecentriq, Rituximab, Mabthera, Gemcitabine 1000 mg, Oxaliplatin 100 MG
University Hospital Southampton NHS Foundation Trust, Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
01/21
11/21
HOVON 151, NCT03463057 / 2017-002605-35: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

Active, not recruiting
2
109
Europe
Atezolizumab, Tecentriq, L01XC
Stichting Hemato-Oncologie voor Volwassenen Nederland
NHL, DLBCL
01/24
01/27
NCT05404048 / 2021-005192-39: PD-L1 PET-imaging During CAR T-cell Therapy

Recruiting
2
20
Europe
89Zr-atezolizumab PET-imaging
University Medical Center Groningen
Large B-cell Lymphoma
05/24
05/25
NCT02596971 / 2015-001364-19: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Nov 2022 - Nov 2022: Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Checkmark Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Nov 2015 - Nov 2015: Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Checkmark Initiation in atezolizumab in combination with Gazyva and CHOP for DLBCL
More
Completed
1/2
91
Europe, US, RoW
Atezolizumab, RO5541267; Tecentriq, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, RO5072759, Prednisone, Vincristine, Rituximab
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
04/18
05/20
NCT02729896 / 2015-004845-25: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Jun 2016 - Jun 2016: First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Completed
1/2
36
Europe, US
Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
Hoffmann-La Roche
Lymphoma
09/18
10/19
ZUMA-6, NCT02926833: Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Hourglass Mar 2021 - Dec 2021 : From ZUMA-6 trial in combination with Tecentriq for refractory DLBCL
Checkmark Enrollment completion for P2 ZUMA-6 trial in combination with Tecentriq in refractory DLBCL
Dec 2018 - Dec 2018: Enrollment completion for P2 ZUMA-6 trial in combination with Tecentriq in refractory DLBCL
Checkmark Initiation of P1b/2 combination trial of KTE-C19 with atezolizumab in patients with chemorefractory diffuse large B cell lymphoma
Oct 2016 - Oct 2016: Initiation of P1b/2 combination trial of KTE-C19 with atezolizumab in patients with chemorefractory diffuse large B cell lymphoma
Completed
1/2
37
US
KTE-C19, Axicabtagene ciloleucel, Yescarta®, Atezolizumab, Cyclophosphamide, Fludarabine
Kite, A Gilead Company, Genentech, Inc.
Refractory Diffuse Large B Cell Lymphoma
01/23
01/23
NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Completed
1/2
8
Europe, Canada, US, RoW
Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab
Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
07/23
07/23
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
280
Europe, US, RoW
Glofitamab, RO7082859, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26

Download Options